Tags

Type your tag names separated by a space and hit enter

Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Expert Rev Cardiovasc Ther 2006; 4(3):319-33ER

Abstract

This article examines evidence-based findings in the literature on the efficacy of perindopril 2 mg/indapamide 0.625 mg, a first-line, low-dose antihypertensive drug combination. In regulatory Phase II and III trials, perindopril/indapamide significantly lowered blood pressure compared with other first-line therapies (atenolol, losartan and irbesartan). This was also the case in STRAtegies of Treatment in Hypertension: Evaluation, a postregistration study versus current monotherapies and stepped-care therapy with different classes of antihypertensive agents. The efficacy/safety ratio (both clinical and with regard to laboratory parameters) of perindopril/indapamide was good. Perindopril/indapamide provides additional antihypertensive efficacy compared with each component used alone and with current monotherapies, with major efficacy on systolic blood pressure, an important predictor of cardiovascular risk. It also reduces pulse pressure, an independent cardiovascular risk factor, large-vessel arterial stiffness and microcirculatory alterations. The fixed dosage of a once-daily tablet, ensures optimal ease of use and enhances patient compliance. Perindopril/indapamide also reduces target organ damage in patients at high cardiovascular risk, such as patients with cardiac hypertrophy and Type 2 diabetics with albuminuria. These benefits, together with the good efficacy/tolerability ratio, fulfill the requirements of the European Society of Hypertension and of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines for low-dose, first-line combination therapy in hypertension.

Authors+Show Affiliations

Cardiologie/Hypertension Artérielle Hopital, Saint André, CHU Bordeaux, 1 rue Jean Burguet, 33075, Bordeaux, France. philippe.gosse@chu-bordeaux.fr

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

16716093

Citation

Gosse, Philippe. "Perindopril/indapamide Combination in the First-line Treatment of Hypertension and End-organ Protection." Expert Review of Cardiovascular Therapy, vol. 4, no. 3, 2006, pp. 319-33.
Gosse P. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. Expert Rev Cardiovasc Ther. 2006;4(3):319-33.
Gosse, P. (2006). Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. Expert Review of Cardiovascular Therapy, 4(3), pp. 319-33.
Gosse P. Perindopril/indapamide Combination in the First-line Treatment of Hypertension and End-organ Protection. Expert Rev Cardiovasc Ther. 2006;4(3):319-33. PubMed PMID: 16716093.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. A1 - Gosse,Philippe, PY - 2006/5/24/pubmed PY - 2006/8/17/medline PY - 2006/5/24/entrez SP - 319 EP - 33 JF - Expert review of cardiovascular therapy JO - Expert Rev Cardiovasc Ther VL - 4 IS - 3 N2 - This article examines evidence-based findings in the literature on the efficacy of perindopril 2 mg/indapamide 0.625 mg, a first-line, low-dose antihypertensive drug combination. In regulatory Phase II and III trials, perindopril/indapamide significantly lowered blood pressure compared with other first-line therapies (atenolol, losartan and irbesartan). This was also the case in STRAtegies of Treatment in Hypertension: Evaluation, a postregistration study versus current monotherapies and stepped-care therapy with different classes of antihypertensive agents. The efficacy/safety ratio (both clinical and with regard to laboratory parameters) of perindopril/indapamide was good. Perindopril/indapamide provides additional antihypertensive efficacy compared with each component used alone and with current monotherapies, with major efficacy on systolic blood pressure, an important predictor of cardiovascular risk. It also reduces pulse pressure, an independent cardiovascular risk factor, large-vessel arterial stiffness and microcirculatory alterations. The fixed dosage of a once-daily tablet, ensures optimal ease of use and enhances patient compliance. Perindopril/indapamide also reduces target organ damage in patients at high cardiovascular risk, such as patients with cardiac hypertrophy and Type 2 diabetics with albuminuria. These benefits, together with the good efficacy/tolerability ratio, fulfill the requirements of the European Society of Hypertension and of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines for low-dose, first-line combination therapy in hypertension. SN - 1744-8344 UR - https://www.unboundmedicine.com/medline/citation/16716093/Perindopril/indapamide_combination_in_the_first_line_treatment_of_hypertension_and_end_organ_protection_ L2 - http://www.tandfonline.com/doi/full/10.1586/14779072.4.3.319 DB - PRIME DP - Unbound Medicine ER -